



SUJEET KUMAR

klempharma@gmail.com

(Scopus: 57209050828,

Publons: AAD-5081-2019)

• **CURRENT POSITION**

Postdoctoral Researcher, PNU, Republic of Korea

Since, Oct 2018

• **TEACHING EXPERIENCE**

Department of Pharmaceutical Chemistry
(KLE College of Pharmacy, Bengaluru)

July 2007 - Sept 2018

• **AREA OF RESEARCH**

I am a medicinal chemist love to work on design and development of heterocyclic moiety with anti-cancer property. Development of stimuli responsive and targeted drug delivery system is my new area of research.

• **PATENT (INDIAN)**

Novel inhibitors of anti-apoptotic BCL-2 Proteins

• **FELLOWSHIP**

Summer Research Fellowship Program-2018

June-July 2018

Sponsor: Indian Academy of Sciences, IISc., Bengaluru

Host Institute: IUCBR &SSH, Kottayam

Summer Research Fellowship Program -2017

July-Aug 2017

Sponsor: Indian Academy of Sciences, IISc., Bengaluru

Host Institute: BARC, Mumbai

• **AWARDS AND RECOGNITION**

Best teacher award for the year of 2018-19 by KLE Academy of Higher Education and Research, Belagavi

• **TRAINING PROGRAMS**

Quality Improvement Program

Nov 2016 (21st- 25th)

Title: Applications for NMR spectroscopy in structural and conformational analysis

Host Institute: Indian Institute of Science, Bengaluru

Centre for Continuing Education

Jan - May 2016

Title: NMR and its applications in biology

Host Institute: Indian Institute of Science, Bengaluru

• EDUCATIONAL QUALIFICATION

(Registered Pharmacist @ KSPC, Bengaluru)

Doctor of Philosophy (PhD)

Oct 2017

Faculty: Pharmaceutical Sciences

University: Jawaharlal Nehru Technological University, Hyderabad

Master of Pharmacy

Sept 2007

Specialization: Pharmaceutical Chemistry

Institute/University: KLES College of Pharmacy, Rajiv Gandhi University for Health Sciences, Bengaluru

Bachelor of Pharmacy

May 2002

Institute/University: KLES College of Pharmacy, Rajiv Gandhi University for Health Sciences, Bengaluru

❖ SELECTED PUBLICATIONS

Pandey, M., **Kumar, S.**, Goldsmith, G., Srivastava, M., Elango, S., Shameem, M., Bannerjee, D., Choudhary, B., Karki, S.S., and Raghavan, S.C. (2017). Identification and characterization of novel ligase-I inhibitors. *Molecular Carcinogenesis*.56:550-66.

Thomas, E., Gopalakrishnan, V., Hegde, M., **Kumar, S.**, Karki, S.S., Raghavan, S.C., and Choudhary, B. (2016). A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells. *Scientific Reports*.6e :34653.

Kumar S., Metikurki B., Bhaduria V.S., Schols E.D., Tokuda H., and Karki S.S. (2016). Synthesis of imidazo[2,1-*b*][1,3,4]-thiadiazole derivatives as possible biologically active agents. *Acta Poloniae Pharmaceutica Drug Research*. 73:913-29.

Kumar, S., Gopalakrishnan, V., Hegde, M., Rana, V., Dhepe, S.S., Ramareddy, S.A., Leoni, A., Locatelli, A., Morigi, R., Rambaldi, M., Srivastava M., Raghavan S.C., and Karki, S.S.(2014). Synthesis and antiproliferative activity of imidazo[2,1-*b*][1,3,4]thiadiazole derivatives. *Bioorganic & Medicinal Chemistry Letters*. 24:4682-88.

Kumar, S., Hegde, M., Gopalakrishnan, V., Renuka, V.K., Ramareddy, S.A., De Clercq, E., Schols, D., Narasimhamurthy, G.A.K., Raghavan, S.C., and Karki, S.S. (2014). 2-(4-Chlorobenzyl)-6-arylimidazo[2,1-*b*][1,3,4]thiadiazoles: synthesis, cytotoxic activity and mechanism of action. *European Journal of Medicinal Chemistry*.84:687-97.

Srivastava, M., Nambiar, M., Sharma, S., Karki, S.S., Goldsmith, G., Hegde, M., **Kumar, S.**, Pandey, M., Singh, R.K., Ray, P., Natarajan, R., Kelkar, M., De, A., Choudhary B., and Raghavan, S.C. (2012). An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. *Cell*. 151:1474-87.

SUJEET KUMAR